Professional Overview
Arshad Mujeebuddin is a seasoned executive in the pharmaceutical industry, currently serving as Vice President Patient Safety Alexion Rare Disease at AstraZeneca. His key expertise areas include patient safety, pharmacovigilance, and medical affairs, with a focus on rare diseases.
Experience Summary
Current Role
As Vice President Patient Safety Alexion Rare Disease, Arshad is responsible for ensuring the safety of patients treated with rare disease medications. His key responsibilities include overseeing pharmacovigilance operations, collaborating with cross-functional teams to develop safety strategies, and providing medical expertise to support regulatory submissions.
Notable achievements in his current role are not available.
Career Progression
Arshad's career progression is marked by significant growth and increasing responsibility. Previously, he held various roles at Alexion Pharmaceuticals, Inc., including Executive Medical Director, Senior Medical Director of Pharmacovigilance, and Medical Director of Pharmacovigilance. Earlier in his career, he worked as a Drug Safety Physician and Clinical Research Associate at SGS Life Science Services and Clinilabs, respectively.
Areas of Expertise
Arshad possesses industry-specific skills in pharmacovigilance, medical affairs, and clinical research. His technical competencies include expertise in regulatory compliance, risk management, and safety surveillance. As a seasoned leader, he has demonstrated strong leadership and management capabilities, with experience in overseeing cross-functional teams and driving strategic initiatives.
Professional Impact
Although specific details on notable projects or initiatives are not available, Arshad's work in patient safety and pharmacovigilance has likely contributed to improved outcomes for patients with rare diseases.
Conclusion
Arshad Mujeebuddin is a dedicated and experienced pharmaceutical executive with a strong background in patient safety, pharmacovigilance, and medical affairs. Currently, he is focused on ensuring the safety of patients treated with rare disease medications. With his expertise and leadership capabilities, he is well-positioned to drive strategic initiatives and contribute to the growth and success of AstraZeneca.
